Back to top
more

Horizon Therapeutics Public Limited Company (HZNP)

(Delayed Data from NSDQ)

$109.71 USD

109.71
1,623,606

+1.76 (1.63%)

Updated Sep 17, 2021 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy25.60%
2Buy19.21%
3Hold10.85%
4Sell6.62%
5Strong Sell3.32%
S&P50011.33%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 22% (197 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Trades from $1

Zacks News

Aerie (AERI) Announces Mixed Data From Dry Eye Disease Study

Aerie Pharmaceuticals (AERI) reports mixed data from the phase IIb study evaluating AR-15512 for treating dry eye disease. Resultantly, the stock declines in after-market trading on Sep 15.

Here's Why You Should Retain QIAGEN (QGEN) Stock For Now

Investors are optimistic about QIAGEN (QGEN) owing to impressive sales of diagnostic solutions and strong international growth.

3 Reasons Why Horizon Therapeutics (HZNP) Is a Great Growth Stock

Horizon Therapeutics (HZNP) could produce exceptional returns because of its solid growth attributes.

Is Horizon (HZNP) a Great Growth Stock?

If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider Horizon (HZNP).

Horizon (HZNP) Begins Phase IV Study on Tepezza for Chronic TED

Horizon (HZNP) enrolls the first patient in a phase IV study evaluating the safety and efficacy of Tepezza for the treatment of chronic (inactive) thyroid eye disease.

Here's Why Momentum Investors Will Love Horizon Therapeutics (HZNP)

Does Horizon Therapeutics (HZNP) have what it takes to be a top stock pick for momentum investors? Let's find out.

Why Is Horizon Therapeutics (HZNP) Up 3.7% Since Last Earnings Report?

Horizon Therapeutics (HZNP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Techne (TECH) Soars to 52-Week High, Time to Cash Out?

Techne (TECH) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Anixa (ANIX) Ovarian Cancer CAR-T Drug to Enter Clinical Study

The FDA clears Anixa Biosciences' (ANIX) application to initiate clinical studies for its ovarian cancer CAR-T therapy. The stock rises following the announcement.

BioMarin's (BMRN) Dwarfism Drug Gets Approval in Europe

Biomarin Pharmaceutical's (BMRN) Voxzogo is the first medicine in Europe to be approved to treat achondroplasia, the most common form of dwarfism.

AstraZeneca's (AZN) Rare Disease Study Meets Primary Goal

AstraZeneca's (AZN) phase III study evaluating ALXN1840 for Wilson disease achieves primary endpoint. The company also receives approval in Japan for Forxiga to treat chronic kidney disease.

Regeneron's (REGN) Wet AMD Study on High Dose Eylea Meets Goal

Regeneron's (REGN) phase II study evaluating a higher 8-mg dose of Eylea injection in patients with wet age-related macular degeneration has met the primary safety endpoint.

Novartis (NVS) Kymriah Misses Primary Endpoint in NHL Study

Novartis' (NVS) phase III study evaluating Kymriah for second-line treatment of patients with aggressive B-cell NHL fails to achieve primary endpoint of the study.

Axsome's (AXSM) Stock Up Despite FDA Delay on Depression Drug

FDA delays decision on Axsome Therapeutics' (AXSM) new drug application for AXS-05, a potential treatment for major depressive disorder.

CARA Drug Wins FDA Nod for Pruritus Associated With CKD

CARA gets a significant boost with FDA approval for Korsuva injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis.

QIAGEN's (QGEN) Kits Hit New Milestone for Sample Preparation

QIAGEN's (QGEN) consumables kits have been utilized to process more than 3 billion biological samples, emphasizing on its leading position in sample preparation.

Bristol Myers' (BMY) Opdivo Approved for Another Indication

Bristol Myers' (BMY) Opdivo gets label expansion in the United States for adjuvant treatment of patients with high-risk urothelial carcinoma.

J&J (JNJ) CEO Alex Gorsky to Resign, Joaquin Duato to Succeed

J&J's (JNJ) CEO Alex Gorsky who has led the company for almost a decade resigns. Joaquin Duato to succeed as CEO.

AzurRx (AZRX) Pancreatic Insufficiency Study Meets Endpoints

AzurRx (AZRX) is developing lead pipeline candidate as monotherapy and in combination regimen as potential treatment for exocrine pancreatic insufficiency in patients with cystic fibrosis.

Agios (AGIO) Rare Disease Drug NDA Gets FDA Priority Review

Agios (AGIO) is seeking approval for its lead pipeline candidate, mitapivat, as a potential treatment for PK deficiency.

Travere (TVTX) Announces Data on Rare Kidney Disease Drug

Travere (TVTX) announces positive interim data from the ongoing study of its investigational candidate, sparsentan, for the treatment of IgAN, a rare kidney disorder. Resultantly, the stock rises

Moderna (MRNA) Begins Rare Disease Study, Inks Supply Agreement

Moderna (MRNA) doses first patient in phase I/II study with mRNA-3705 for the treatment of a rare multi-organ disorder. The company also revises the supply agreement with the Canadian Government for its COVID vaccine.

Lilly (LLY) Phase III Eczema Study on Lebrikizumab Meets Goal

Eli Lilly's (LLY) two phase III studies on lebrikizumab meet the primary and all key secondary endpoints.

Jazz's (JAZZ) Xywav Gets FDA Nod for Idiopathic Hypersomnia

Jazz's (JAZZ) Xywav gets FDA approval for new indication, idiopathic hypersomnia. Following approval, Xywav becomes the first drug for treatment of this sleep disorder.

Is Horizon Therapeutics (HZNP) a Great Growth Stock?

If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider Horizon Therapeutics (HZNP).